Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
3841-3860 of 3,900 trials

ARGX-121: Safety Study in Healthy Adults

We are assessing the safety of the new treatment ARGX-121 in healthy adult participants. This study aims to ensure the treatment is safe for future use.

Healthy Volunteers6-12 monthsSafety phase (I)AllergologyInfectious Diseases

Advanced-Stage Solid Tumors: JNJ-95437446

We are testing a new treatment for people with advanced-stage solid tumors to see how safe it is and determine the right dosage. This study aims to gather important information for future cancer therapies.

Non-Small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Squamous Cell Carcinoma of the Head and Neck (HNSCC)>2 yearsSafety phase (I)Oncology

BP1.15205: New Oral Medication Study

We are testing a new medication called BP1.15205 in healthy volunteers to see how safe it is and how it works in the body. This study will help us understand its effects, including how food might change its absorption.

NarcolepsySafety phase (I)CardiologyNeurology

Cangrelor for Acute Ischemic Stroke Treatment

We are studying the safety and effectiveness of an intravenous medication called Cangrelor for patients with acute ischemic stroke and significant carotid artery blockage. This trial aims to see if it helps improve blood flow during emergency stenting procedures.

Ischemic Stroke with Large Artery Occlusion>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyNeurology

New Treatment for Patients with XXX Cancer

We are exploring a new combination therapy for people with XXX cancer who need a second-line treatment. The goal is to see if this approach is safer and more effective than standard care.

Cancer Eligible for Second-Line Treatment1-2 yearsSafety phase (I)Oncology

Vormatrigine for Adults with Epilepsy

We are studying the safety and tolerability of vormatrigine in adults with focal or generalized tonic-clonic seizures. We also aim to explore its effects on seizure frequency and overall patient experience.

Focal Epilepsy and Tonic-Clonic EpilepsyConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

EGL-003 for Autoimmune Diseases

We are testing a new treatment called EGL-003 to see how safe it is and how the body handles it. The study starts with healthy volunteers and then includes adults with autoimmune diseases.

Atopic Dermatitis1-2 yearsSafety phase (I)DermatologyRheumatology

Hereditary Angioedema: Navenibart Treatment Study

We are studying whether navenibart can help prevent attacks in adults and adolescents with hereditary angioedema. The trial will also look at its safety and how it affects quality of life.

Hereditary Angioedema1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyInternal Medicine

TAR-0520 Gel for Preventing Nerve Damage in Breast Cancer Patients

We are studying whether TAR-0520 Gel can safely prevent nerve damage and nail changes in patients receiving taxane chemotherapy for breast cancer.

Chemotherapy-Induced Peripheral Neuropathy6-12 monthsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesInternal MedicineNeurologyOncology

Zoldonrasib for RAS G12D-Mutant Non-Small Cell Lung Cancer

We are studying the effects of zoldonrasib in patients with RAS G12D-mutant non-small cell lung cancer who have been previously treated. The goal is to see how well it works and how safe it is compared to existing treatments.

Non-small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Advanced Solid Tumors: MK-1084 Treatment Study

We are studying the effects of MK-1084, both alone and with cetuximab, in patients with advanced solid tumors that have a KRAS G12C mutation. The goal is to see how well these treatments work and how safe they are.

Malignant Neoplasm with KRAS G12C Mutation>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Rheumatoid Arthritis: Tulisokibart Study

We are testing a new medication called tulisokibart for people with rheumatoid arthritis to see if it helps reduce symptoms better than a placebo. The study will also assess the safety and tolerability of this treatment.

Rheumatoid Arthritis1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesRheumatology

Type 2 Diabetes: SGLT-2 Inhibitors and Heart Health

We are studying how SGLT-2 inhibitors may improve heart function and nerve health in people with type 2 diabetes. This research aims to understand the connection between these medications and heart regulation.

Type 2 DiabetesMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCardiologyEndocrinologyNeurology

Lung Cancer: Zipalertinib with Chemotherapy

We are studying whether adding zipalertinib to chemotherapy helps lung cancer patients with uncommon EGFR mutations after surgery. This trial compares the new treatment to a placebo combined with standard chemotherapy.

Non-small Cell Lung Cancer (NSCLC)Confirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementOncology

RSV Immunization Study: Nirsevimab for Infants

We are studying how the nirsevimab immunization affects infants' immune responses to RSV infections. This research aims to understand the role of age, weight, and maternal antibodies in developing immunity.

Healthy Infants1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology

NTX-1955: Effects on Brain Function

We are examining how the oral medication NTX-1955 affects the brain in healthy adults. This study aims to gather insights that could inform future treatments.

Generalized Anxiety Disorder6-12 monthsSafety phase (I)Psychiatry

Bile Acid Diarrhea: Atorvastatin Treatment Study

We are investigating whether atorvastatin can help reduce bile acid production and improve symptoms in patients with moderate to severe bile acid diarrhea. The study will also look at various health markers and safety.

Bile Acid Diarrhoea3-6 monthsConfirmation phase (III)Monitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementGastroenterology

Familial Polycythemia: New Drug Treatment Study

We are testing a new drug for individuals with familial polycythemia caused by an EPO gene mutation. The goal is to see if it is safe and effective in managing their condition.

Familial Polycythemia with EPO Gene Mutation1-2 yearsSafety phase (I)Hematology

Testing CLE-905-AG for Safety and Tolerability

We are studying a new medication to see how safe it is and how the body handles it in healthy individuals. This trial will also explore its effects when combined with another drug.

Schizophrenia6-12 monthsSafety phase (I)Psychiatry

LY3537031 for Liver Function Study

We are investigating how LY3537031 affects people with normal liver function and those with mild to severe liver impairment. This study aims to learn more about its safety and effectiveness in different liver health conditions.

Healthy Participants6-12 monthsSafety phase (I)HepatologyInternal Medicine